Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860961 · ClinicalTrials.gov registry record · NA
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
A NA study of Prostate Adenocarcinoma, sponsored by NRG Oncology.
- Completed
- Registry status
- NA
- Development phase
- 550
- Enrollment target
- 20
- Study locations
NCT03860961 is a NA study of Prostate Adenocarcinoma that has completed, run by NRG Oncology. The registered enrollment target is 550 participants, above the 213-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (158% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03860961, a NA study of Prostate Adenocarcinoma, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- NA
- Development phase
- 550 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. This is especially important for prostate cancer survivors who need routine cancer care follow-up with their radiation oncologist and also coordinated routine follow-up with their primary care provider (PCP). This is important because androgen deprivation therapy increases a patient's risk for developing diabetes, hypercholesterolemia, and cardiovascular events. Increasing the dose of survivorship may improve care and outcomes of cancer survivors than standard practices.
Conditions Studied
Interventions
- OTHER Treatment Plan
- OTHER Survivorship Care Plan
Study Locations (20)
California
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente Oakland-Broadway - Oakland
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Rohnert Park Cancer Center - Rohnert Park
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente Cancer Treatment Center - South San Francisco
Idaho
- Saint Luke's Cancer Institute - Boise - Boise
- Saint Luke's Cancer Institute - Fruitland - Fruitland
- Saint Luke's Cancer Institute - Meridian - Meridian
- Saint Luke's Cancer Institute - Nampa - Nampa
- Saint Luke's Cancer Institute - Twin Falls - Twin Falls
Delaware
- Helen F Graham Cancer Center - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Beebe Health Campus - Rehoboth Beach
Illinois
- John H Stroger Jr Hospital of Cook County - Chicago
- Carle at The Riverfront - Danville
Arizona
- Kingman Regional Medical Center - Kingman
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Georgia
- Augusta University Medical Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2025-09-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860961
The ClinicalTrials.gov registry entry for NCT03860961 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 213-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (158% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Treatment Plan is the first listed.
NCT03860961 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Idaho, Delaware.
Frequently Asked Questions
What is clinical trial NCT03860961 about?
NCT03860961 is a clinical study titled "Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy". This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy. There is a need for coordinated care between the cancer care team with the primary care team. This is es...
What is the current status of trial NCT03860961?
This trial is currently completed. It is a NA study. The enrollment target is 550 participants. The study started on 2019-07-26. Estimated completion is 2025-09-04.
What conditions does trial NCT03860961 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT03860961?
The interventions under investigation include: Treatment Plan (OTHER), Survivorship Care Plan (OTHER).
Who is sponsoring clinical trial NCT03860961?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03860961 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
RECRUITING · NA
-
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
RECRUITING · NA
-
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
-
Two-fraction HDR Monotherapy for Localized Prostate Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.